UDR, Inc. (UDR) Reaches $40.46 52-Week High, Midatech Pharma PLC (LON:MTPH) Covered By 2 Bullish Analysts Last Week

June 19, 2017 - By Kurt Siggers

Among 2 analysts covering Midatech Pharma Plc (LON:MTPH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Midatech Pharma Plc had 33 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, January 6 by N+1 Singer. N+1 Singer maintained Midatech Pharma PLC (LON:MTPH) on Friday, January 20 with “Buy” rating. The rating was maintained by Panmure Gordon on Wednesday, May 18 with “Buy”. On Monday, May 22 the stock rating was maintained by Panmure Gordon with “Buy”. The stock of Midatech Pharma PLC (LON:MTPH) earned “Buy” rating by Panmure Gordon on Friday, January 20. The stock of Midatech Pharma PLC (LON:MTPH) earned “Buy” rating by N+1 Singer on Monday, May 15. The rating was maintained by Panmure Gordon on Tuesday, November 22 with “Buy”. The stock of Midatech Pharma PLC (LON:MTPH) earned “Buy” rating by Panmure Gordon on Wednesday, April 13. The stock of Midatech Pharma PLC (LON:MTPH) earned “Buy” rating by N+1 Singer on Tuesday, April 4. Panmure Gordon maintained the shares of MTPH in report on Wednesday, September 21 with “Buy” rating. See Midatech Pharma PLC (LON:MTPH) latest ratings:

22/05/2017 Broker: N+1 Singer Rating: Buy New Target: GBX 140.00 Maintain
22/05/2017 Broker: Panmure Gordon Rating: Buy Old Target: GBX 297.00 New Target: GBX 297.00 Maintain
15/05/2017 Broker: N+1 Singer Rating: Buy New Target: GBX 140.00 Maintain
20/04/2017 Broker: Panmure Gordon Rating: Buy Old Target: GBX 297.00 New Target: GBX 297.00 Maintain
04/04/2017 Broker: Panmure Gordon Rating: Buy Old Target: GBX 297.00 New Target: GBX 297.00 Maintain
04/04/2017 Broker: N+1 Singer Rating: Buy New Target: GBX 283.00 Maintain
10/03/2017 Broker: Panmure Gordon Rating: Buy Old Target: GBX 297.00 New Target: GBX 297.00 Maintain
20/01/2017 Broker: N+1 Singer Rating: Buy New Target: GBX 283.00 Maintain
20/01/2017 Broker: Panmure Gordon Rating: Buy Old Target: GBX 297.00 New Target: GBX 297.00 Maintain

The stock of UDR, Inc. (NYSE:UDR) hit a new 52-week high and has $42.08 target or 4.00% above today’s $40.46 share price. The 6 months bullish chart indicates low risk for the $10.87B company. The 1-year high was reported on Jun, 19 by Barchart.com. If the $42.08 price target is reached, the company will be worth $434.80 million more. About 86,979 shares traded. UDR, Inc. (NYSE:UDR) has risen 7.20% since June 19, 2016 and is uptrending. It has underperformed by 9.50% the S&P500.

About shares traded. Midatech Pharma PLC (LON:MTPH) has 0.00% since June 19, 2016 and is . It has underperformed by 16.70% the S&P500.

Midatech Pharma PLC is an early-stage biopharmaceutical firm that focuses on commercializing and developing products in oncology and other therapeutic areas. The company has market cap of 54.57 million GBP. The Company’s divisions include Pipeline Research and Development, and Commercial. It currently has negative earnings. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Among 21 analysts covering UDR Inc (NYSE:UDR), 4 have Buy rating, 4 Sell and 13 Hold. Therefore 19% are positive. UDR Inc had 41 analyst reports since July 21, 2015 according to SRatingsIntel. BMO Capital Markets downgraded UDR, Inc. (NYSE:UDR) on Tuesday, October 25 to “Market Perform” rating. The stock of UDR, Inc. (NYSE:UDR) has “Underperform” rating given on Thursday, August 20 by Credit Suisse. RBC Capital Markets maintained UDR, Inc. (NYSE:UDR) on Monday, November 9 with “Sector Perform” rating. As per Friday, December 16, the company rating was downgraded by JP Morgan. The stock of UDR, Inc. (NYSE:UDR) has “Neutral” rating given on Wednesday, March 8 by Bank of America. The firm has “Buy” rating given on Thursday, August 25 by BTIG Research. The rating was downgraded by Bank of America to “Underperform” on Monday, April 11. The stock has “Neutral” rating by Credit Suisse on Tuesday, October 27. SunTrust upgraded the shares of UDR in report on Friday, January 20 to “Buy” rating. As per Tuesday, December 13, the company rating was downgraded by Morgan Stanley.

Investors sentiment increased to 1.04 in 2016 Q4. Its up 0.08, from 0.96 in 2016Q3. It increased, as 31 investors sold UDR, Inc. shares while 107 reduced holdings. 37 funds opened positions while 106 raised stakes. 261.95 million shares or 1.17% less from 265.03 million shares in 2016Q3 were reported. Los Angeles Capital Management And Equity Research has 258,677 shares. Sumitomo Mitsui Tru Holdg reported 1.01 million shares. Bnp Paribas Prns reported 0% of its portfolio in UDR, Inc. (NYSE:UDR). Citigroup accumulated 0% or 141,828 shares. Markston Int Ltd Liability, a New York-based fund reported 364,628 shares. Wells Fargo & Mn holds 0% in UDR, Inc. (NYSE:UDR) or 139,730 shares. Northern Tru Corporation holds 0.04% or 3.92 million shares. 3,473 were accumulated by Qs Lc. Moreover, Cap Mngmt Va has 0.09% invested in UDR, Inc. (NYSE:UDR). Metropolitan Life Ins Company Ny invested in 0.04% or 148,163 shares. Fmr accumulated 0.1% or 20.70M shares. National Bank & Trust Of America De accumulated 0.01% or 1.13 million shares. 287 are held by Gemmer Asset. Schwab Charles Invest Mgmt reported 2.40M shares. Heritage Wealth Advsr stated it has 0.39% of its portfolio in UDR, Inc. (NYSE:UDR).

Analysts await UDR, Inc. (NYSE:UDR) to report earnings on July, 25. They expect $0.46 EPS, up 4.55% or $0.02 from last year’s $0.44 per share. UDR’s profit will be $123.58M for 21.99 P/E if the $0.46 EPS becomes a reality. After $0.45 actual EPS reported by UDR, Inc. for the previous quarter, Wall Street now forecasts 2.22% EPS growth.

Since December 21, 2016, it had 0 insider buys, and 5 insider sales for $2.88 million activity. Shares for $542,315 were sold by Troupe Warren L. ALCOCK HARRY G also sold $254,979 worth of UDR, Inc. (NYSE:UDR) shares. $961,250 worth of UDR, Inc. (NYSE:UDR) shares were sold by TOOMEY THOMAS W. GROVE JON A sold $453,186 worth of stock.

UDR, Inc. is a self-administered real estate investment trust. The company has market cap of $10.87 billion. The Firm owns, operates, acquires, renovates, develops, redevelops, disposes of and manages multifamily apartment communities generally located in various markets across the United States. It has a 114.74 P/E ratio. The Company’s divisions are Same-Store Communities and Non-Mature Communities/Other.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: